Asset Details
Do you wish to reserve the book?
Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study
Do you wish to request the book?
Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study
2012
Overview
Purpose
Previous studies established the safety of continuous gefitinib 250 or 500 mg daily. It was postulated that a higher dose may have increased efficacy by inhibiting signaling in both the mitogen-activated protein kinase and AKT pathways. This study investigated the tolerability, pharmacokinetics, and antitumor activity of high-dose gefitinib in patients with refractory solid malignancies.
Methods
Sequential cohorts received oral gefitinib once or twice-weekly, with dose escalation from 1,500 to 3,500 mg.
Results
Twenty-three patients received gefitinib at seven dose levels (1,500, 2,000, 2,500, 3,000, and 3,500 mg once-weekly; 1,500 and 2,000 mg twice-weekly). Gefitinib was well tolerated, with no dose-limiting toxicities. The maximum tolerated dose was not reached. The most common gefitinib-related adverse events were nausea and diarrhea, vomiting, and rash. Pharmacokinetic data demonstrated no consistent increase in exposure to gefitinib with increasing dose across cohorts. Consequently, the study was stopped early and gefitinib 2,000 mg twice-weekly was the highest dose administered. One of eight patients with non-small-cell lung cancer achieved a partial response.
Conclusions
Exposure to gefitinib did not increase consistently with increasing dose beyond gefitinib 1,500 mg once-weekly or twice-weekly. These data do not support further evaluation of gefitinib at high-dose schedules.
Publisher
Springer-Verlag,Springer,Springer Nature B.V
Subject
/ Adult
/ Aged
/ Antineoplastic Agents - administration & dosage
/ Antineoplastic Agents - adverse effects
/ Antineoplastic Agents - pharmacokinetics
/ Biological and medical sciences
/ Dose-Response Relationship, Drug
/ Female
/ Humans
/ Male
/ Medicine
/ Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
/ Oncology
/ Pharmacology. Drug treatments
/ Quinazolines - administration & dosage
/ Quinazolines - adverse effects
/ Quinazolines - pharmacokinetics
/ Tumors
